CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...

A recent Science study explored how intranuclear metabolic enzymes establish the link between locus-specific epigenetic reprogramming of T cells and nutrient availability. Persistent antigen ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...